Entering the Start-up phase of the Breast Cancer Startup Challenge (http://breastcancerstartupchallenge.com), Mesopharm Therapeutics officially launches on April 7th, 2014. Our goal is to revolutionize cancer therapies by combining state of the art therapeutics and theranostics.Our talented team brings together people with diverse expertise and backgrounds from Stanford University (USA), University of Auckland (New Zealand), and University Medical Center Utrecht (Netherlands), reflecting the power of multidisciplinary and global collaboration.

OUR MISSION: Breast Cancer is the most common cause of death in women (521 000 deaths in 2012), affecting 6.3 million people worldwide. WHO recently reported that breast cancer incidence has increased by more than 20%, while mortality has increased by 14% (Source:WHO) and called for immediate attention to address this sharp increase. At Mesopharm, we envision to develop first-in-class biological therapies at a pre-clinical stage and accelerate their transition into the clinic. Our flagship drug candidates target specific transmembrane protein that is highly expressed in breast cancer and other tumors. We plan to extend our therapies beyond breast cancer to other devastating cancers where our drug candidates show indication for therapeutic use. KEY ACTIVITIES:

Mesopharm launches on April 7th, 2014!!!!

At the full gear on drafting business plan for submitting licensing application on April 15th, 2014.

Initiated engagement with the National Cancer Institute and Dr. Mitchell Ho (the inventor of the technology) to develop a CRADA (Collaborative Research and Development Agreement).

Have successfully secured full support of chemistry expertise on therapeutic drug development from the Auckland Cancer Society Research Centre.

Arranged a series of meetings to seed funders and seasoned entrepreneurs.